DCPXF (DanCann Pharma AS) Non Operating Income: $0.00 Mil (TTM As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DCPXF DanCann Pharma AS DCPXF
20 GF Score
Price $10.00
GF Value $37.14
! 3 Warning Signs
View Full Analysis

What is DanCann Pharma AS Non Operating Income?

DanCann Pharma AS DCPXF 20 Non Operating Income is $0.00 Mil as of Sep. 2025. GuruFocus rates DCPXF with a GF Score™ of 20/100 and a GF Value™ of $37.14. The stock has 3 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. DanCann Pharma AS's Non Operating Income for the three months ended in Sep. 2025 was $0.00 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Sep. 2025 was $0.00 Mil.

DanCann Pharma AS Non Operating Income Related Terms

DanCann Pharma AS Non Operating Income Historical Data

* Premium members only.

The historical data trend for DanCann Pharma AS's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DanCann Pharma AS Non Operating Income Chart

DanCann Pharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Non Operating Income
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

DanCann Pharma AS Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DCPXF
20GF Score
DanCann Pharma AS DCPXF
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DanCann Pharma AS Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $0.00 Mil mean?
DanCann Pharma AS (DCPXF) has a Non Operating Income of $0.00 Mil as of Sep. 2025. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on DanCann Pharma AS and its competitors.
Is DanCann Pharma AS's Non Operating Income too high?
DanCann Pharma AS's current Non Operating Income is $0.00 Mil. Overall, DanCann Pharma AS has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does DanCann Pharma AS's Non Operating Income compare to ZTS and UTHR?
DanCann Pharma AS's Non Operating Income of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Drug Manufacturers company?
A good Non Operating Income depends on the Drug Manufacturers industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on DanCann Pharma AS and its competitors. DanCann Pharma AS's current Non Operating Income is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DanCann Pharma AS stock overvalued right now?
DanCann Pharma AS (DCPXF) has a current Non Operating Income of $0.00 Mil. The stock's GF Value™ is $37.14, compared to a current price of $10.00 — trading 73.1% below its estimated fair value. The current Non Operating Income is $0.00 Mil. DanCann Pharma AS's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For DanCann Pharma AS (DCPXF), the current Non Operating Income is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DanCann Pharma AS (DCPXF) Overvalued in 2026?

Based on GuruFocus' analysis, DanCann Pharma AS stock appears to be undervalued. The current stock price of $10.00 is trading 73.1% below its estimated GF Value™ of $37.14.

Key valuation signals for DCPXF:

  • Non Operating Income: $0.00 Mil
  • GF Value™: $37.14 vs. price of $10.00 (73.1% below fair value)
  • GF Score™: 20/100 with 3 warning signs

No single metric tells the full story. See the DCPXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DanCann Pharma AS Business Description

Address Rugvaenget 5, Ansager, DNK, DK-6823
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
20GF Score

Get the complete analysis for DCPXF

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.00
Price
$37.14
GF Value